Cafa, Yes, I have no argument with what you're saying, and...

Cafa,

Yes, I have no argument with what you're saying, and thanks again for posting that abstract. It seems, though, that TheraSpheres currently has first-mover advantage in HCC while SIR-Spheres has first-mover advantage in mCRC. If we get to a stage when both products are considered to have more or less equal effectiveness in treating both HCC and mCRC it gets down to a battle of marketing, pricing and, dare I say, patriotism in certain markets.

I wouldn't say I'm worried about SRX's ability to be effective in marketing, but I don't have any data about how effective they have been when there has been some competition. There are plenty of examples around of companies with great products but poor marketing who have lost out to the competition.

Just another little unknown to add into the equation at some point.